Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Catherine Kegakilwe Koofhethile has a total of 166 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Perceptions of young people living with HIV and caregivers in Botswana on analytical treatment interruption studies: a qualitative approach

    by Catherine K. Koofhethile, Poloko Kebaabetswe, Ontlametse T. Choga, Fikile Ditshweu, Pearl Ntshonga, Bonolo R. Molefe, Oganne Batlang, Patrick Mokgethi, Tsholofelo Mosielele, Phenyo Sabone, et al.

    Current research suggests that post-treatment HIV control may be possible for some people following antiretroviral treatment (ART) interruption. Although closely monitored analytic treatment interruption (ATI) studies can be performed safely and are crucial to determine who may no longer require ART, currently it is unknown how acceptable these studies will be in Botswana. To determine the knowledge, attitudes and acceptability of ATI-inclusive studies in Botswana. We employed a non-randomized purposive design to recruit study participants. We conducted face-to-face open-ended interviews with 12 young people living with HIV and 8 caregivers, 8 healthcare providers and 4 community advocates in Gaborone and Palapye. Thirty-two (32) participants consented to be interviewed. The median age of young people living with HIV was 29 years. All young people living with HIV indicated that they were on ART and acknowledged the benefits of being on ART. All young people living with HIV were unaware of ATIs, whereas 6 out of 8 caregivers, 6 out of 8 healthcare providers and 2 out of 4 community advocates had never heard of ATIs. Most participants found ATI research to be acceptable and believed that it would be beneficial provided there were adequate risk mitigations in place. ATI studies were acceptable to both young people living with HIV and their caregivers. There was limited knowledge about ATI, highlighting a need to inform communities and health care providers on the scientific aspects of ATI and HIV cure research.


  • Open Access

    OA-770 Treatment outcomes of low-level viremia among adults living with HIV on dolutegravir-based first line antiretroviral therapy in Botswana

    by Ontlametse T Bareng, Sikhulile Moyo, Mbatshi Mudanga, Kagiso Sebina, Catherine Koofhethile, Wonderful Choga, Irene Gobe, Modisa Motswaledi, Docas Maruapula, Natasha Moraka, et al.

    Background We evaluated the treatment outcomes of individuals experiencing low-level viremia (LLV) on dolutegravir (DTG) based first-line antiretroviral therapy (ART) in Botswana by determining the trends of LLV over a period of 6 years. Methods We used a large national observational cohort of individuals (aged≥18yrs) who initiated on DTG-based first-line ART for at least 3 months from June 2016 to December 2022. The prevalence of viral suppression (VL ≤50copies/mL), low-level viremia (VL:51-999copies/mL) and virologic failure (VF) (any VL>1000copies/mL) were estimated among PLWH. The prevalence of LLV was further classified into LLV ranges (low-LLV:VL:51-200copies/mL, medium-LLV:201-400copies/mL and high-LLV:VL:401-999copies/mL). Univariate and multivariable Cox proportional hazards regression determined whether LLV (exposure) is associated with VF (outcome). Results Among 50,742 PLWH who have at least one VL measurement during the follow-up, the overall prevalence of LLV by duration strata was 2.2%, 1.8%, 1.7%, 2.3%, 3.1%, 3.7% and 3.9% at 0.25-Conclusion The prevalence of LLV ranging from 1.7–3.9% was found in this cohort. Having a high or persistent-LLV is associated with a high risk of subsequent VF. Intensified clinical monitoring strategies are warranted for individuals with LLV.

  • HIV/AIDS Global Epidemic

    by Phyllis J. Kanki, Catherine K. Koofhethile


  • Open Access

    Prediction of Coreceptor Tropism in HIV-1 Subtype C in Botswana

    by Kenanao Kotokwe, Sikhulile Moyo, Melissa Zahralban-Steele, Molly Pretorius Holme, Pinkie Melamu, Catherine Kegakilwe Koofhethile, Wonderful Tatenda Choga, Terence Mohammed, Tapiwa Nkhisang, Baitshepi Mokaleng, et al.

    It remains unknown whether the C-C motif chemokine receptor type 5 (CCR5) coreceptor is still the predominant coreceptor used by Human Immunodeficiency Virus-1 (HIV-1) in Botswana, where the HIV-1 subtype C predominates. We sought to determine HIV-1C tropism in Botswana using genotypic tools, taking into account the effect of antiretroviral treatment (ART) and virologic suppression. HIV-1 gp120 V3 loop sequences from 5602 participants were analyzed for viral tropism using three coreceptor use predicting algorithms/tools: Geno2pheno, HIV-1C Web Position-Specific Score Matrices (WebPSSM) and the 11/25 charge rule. We then compared the demographic and clinical characteristics of people living with HIV (PLWH) harboring R5- versus X4-tropic viruses using χ2 and Wilcoxon rank sum tests for categorical and continuous data analysis, respectively. The three tools congruently predicted 64% of viruses as either R5-tropic or X4-tropic. Geno2pheno and the 11/25 charge rule had the highest concordance at 89%. We observed a significant difference in ART status between participants harboring X4- versus R5-tropic viruses. X4-tropic viruses were more frequent among PLWH receiving ART (χ2 test, p = 0.03). CCR5 is the predominant coreceptor used by HIV-1C strains circulating in Botswana, underlining the strong potential for CCR5 inhibitor use, even in PLWH with drug resistance. We suggest that the tools for coreceptor prediction should be used in combination.


  • Open Access

    HIV-1 reservoir evolution in infants infected with clade C from Mozambique

    by Catherine K. Koofhethile, Stefano Rinaldi, Yelizaveta Rassadkina, Vinh B. Dinh, Ce Gao, Suresh Pallikkuth, Pilar Garcia-Broncano, Lesley R. de Armas, Rajendra Pahwa, Nicola Cotugno, et al.


  • Detection of Inducible Replication-Competent HIV-1 Subtype C Provirus Despite Long-Term Antiretroviral Treatment in Perinatally Infected Adolescents in Botswana

    by Catherine Kegakilwe Koofhethile, Sikhulile Moyo, Kenanao Peggy Kotokwe, Charlotte Ajeong Chang, Patrick Mokgethi, Lorato Muchoba, Selebogo Mokgweetsi, Joseph Makhema, Shahin Lockman, Simani Gaseitsiwe, et al.

    While antiretroviral therapy (ART) effectively suppresses HIV replication, the latent reservoir remains the barrier to HIV eradication. It remains unknown whether long term ART impacts levels of inducible replication-competent provirus. To address this knowledge gap, we assessed the proviral reservoir in HIV-1 perinatally infected adolescents having received ART for over 13 years. We recruited 15 vertically infected adolescents living with HIV in Botswana. Historical viral load, CD4+ T cell count, and treatment data were retrieved from their outpatient medical records. Inducible replication-competent proviruses from cryopreserved peripheral blood mononuclear cells (PBMCs) were quantified using a TZM-bl cell-based assay (TZA). Total proviral DNA copies were quantified using droplet digital PCR (ddPCR). The mean age of study participants was 16 (STD 0.7) years and median CD4+ T cell count at enrollment was 784 (IQR 728.8-1288) cells/mm3. Median age at ART initiation was 8 (IQR 6-12) months. Fourteen (93%) participants had HIV-1 RNA 12 months, p=0.85). The median total HIV DNA count was 129.1 copies/million cells (IQR 18.9–212.3). Our data suggest that long-term ART initiated within the first year in perinatally infected infants did not eliminate proviral DNA or inducible replication-competent proviruses.


  • Open Access

    Sub-Saharan Africa preparedness and response to the COVID-19 pandemic: A perspective of early career African scientists

    by Gisele Umviligihozo, Lucy Mupfumi, Nelson Sonela, Delon Naicker, Ekwaro A. Obuku, Catherine Koofhethile, Tuelo Mogashoa, Anne Kapaata, Geoffrey Ombati, Clive M. Michelo, et al.

    Emerging highly transmissible viral infections such as SARS-CoV-2 pose a significant global threat to human health and the economy. Since its first appearance in December 2019 in the city of Wuhan, Hubei province, China, SARS-CoV-2 infection has quickly spread across the globe, with the first case reported on the African continent, in Egypt on February 14th, 2020. Although the global number of COVID-19 infections has increased exponentially since the beginning of the pandemic, the number of new infections and deaths recorded in African countries have been relatively modest, suggesting slower transmission dynamics of the virus on the continent, a lower case fatality rate, or simply a lack of testing or reliable data. Notably, there is no significant increase in unexplained pneumonias or deaths on the continent which could possibly indicate the effectiveness of interventions introduced by several African governments. However, there has not yet been a comprehensive assessment of sub-Saharan Africa’s (SSA) preparedness and response to the COVID-19 pandemic that may have contributed to prevent an uncontrolled outbreak so far. As a group of early career scientists and the next generation of African scientific leaders with experience of working in medical and diverse health research fields in both SSA and resource-rich countries, we present a unique perspective on the current public health interventions to fight COVID-19 in Africa. Our perspective is based on extensive review of the available scientific publications, official technical reports and announcements released by governmental and non-governmental health organizations as well as from our personal experiences as workers on the COVID-19 battlefield in SSA. We documented public health interventions implemented in seven SSA countries including Uganda, Kenya, Rwanda, Cameroon, Zambia, South Africa and Botswana, the existing gaps and the important components of disease control that may strengthen SSA response to future outbreaks.


  • Open Access

    Sub-Saharan Africa preparedness and response to the COVID-19 pandemic: A perspective of early career African scientists

    by Gisele Umviligihozo, Lucy Mupfumi, Nelson Sonela, Delon Naicker, Ekwaro A. Obuku, Catherine Koofhethile, Tuelo Mogashoa, Anne Kapaata, Geoffrey Ombati, Clive M. Michelo, et al.

    Emerging highly transmissible viral infections such as SARS-CoV-2 pose a significant global threat to human health and the economy. Since its first appearance in December 2019 in the city of Wuhan, Hubei province, China, SARS-CoV-2 infection has quickly spread across the globe, with the first case reported on the African continent, in Egypt on February 14th, 2020. Although the global number of COVID-19 infections has increased exponentially since the beginning of the pandemic, the number of new infections and deaths recorded in African countries have been relatively modest, suggesting slower transmission dynamics of the virus on the continent, a lower case fatality rate, or simply a lack of testing or reliable data. Notably, there is no significant increase in unexplained pneumonias or deaths on the continent which could possibly indicate the effectiveness of interventions introduced by several African governments. However, there has not yet been a comprehensive assessment of sub-Saharan Africa’s (SSA) preparedness and response to the COVID-19 pandemic that may have contributed to prevent an uncontrolled outbreak so far. As a group of early career scientists and the next generation of African scientific leaders with experience of working in medical and diverse health research fields in both SSA and resource-rich countries, we present a unique perspective on the current public health interventions to fight COVID-19 in Africa. Our perspective is based on extensive review of the available scientific publications, official technical reports and announcements released by governmental and non-governmental health organizations as well as from our personal experiences as workers on the COVID-19 battlefield in SSA. We documented public health interventions implemented in seven SSA countries including Uganda, Kenya, Rwanda, Cameroon, Zambia, South Africa and Botswana, the existing gaps and the important components of disease control that may strengthen SSA response to future outbreaks.


  • Open Access

    Sub-Saharan Africa preparedness and response to the COVID-19 pandemic: A perspective of early career African scientists

    by Gisele Umviligihozo, Lucy Mupfumi, Nelson Sonela, Delon Naicker, Ekwaro A. Obuku, Catherine Koofhethile, Tuelo Mogashoa, Anne Kapaata, Geoffrey Ombati, Clive M. Michelo, et al.

    Emerging highly transmissible viral infections such as SARS-CoV-2 pose a significant global threat to human health and the economy. Since its first appearance in December 2019 in the city of Wuhan, Hubei province, China, SARS-CoV-2 infection has quickly spread across the globe, with the first case reported on the African continent, in Egypt on February 14th, 2020. Although the global number of COVID-19 infections has increased exponentially since the beginning of the pandemic, the number of new infections and deaths recorded in African countries have been relatively modest, suggesting slower transmission dynamics of the virus on the continent, a lower case fatality rate, or simply a lack of testing or reliable data. Notably, there is no significant increase in unexplained pneumonias or deaths on the continent which could possibly indicate the effectiveness of interventions introduced by several African governments. However, there has not yet been a comprehensive assessment of sub-Saharan Africa’s (SSA) preparedness and response to the COVID-19 pandemic that may have contributed to prevent an uncontrolled outbreak so far. As a group of early career scientists and the next generation of African scientific leaders with experience of working in medical and diverse health research fields in both SSA and resource-rich countries, we present a unique perspective on the current public health interventions to fight COVID-19 in Africa. Our perspective is based on extensive review of the available scientific publications, official technical reports and announcements released by governmental and non-governmental health organizations as well as from our personal experiences as workers on the COVID-19 battlefield in SSA. We documented public health interventions implemented in seven SSA countries including Uganda, Kenya, Rwanda, Cameroon, Zambia, South Africa and Botswana, the existing gaps and the important components of disease control that may strengthen SSA response to future outbreaks.


  • Open Access

    Undetectable proviral deoxyribonucleic acid in an adolescent perinatally infected with human immunodeficiency virus-1C and on long-term antiretroviral therapy resulted in viral rebound following antiretroviral therapy termination

    by Catherine Kegakilwe Koofhethile, Sikhulile Moyo, Kenanao Peggy Kotokwe, Patrick Mokgethi, Lorato Muchoba, Selebogo Mokgweetsi, Tendani Gaolathe, Joseph Makhema, Roger Shapiro, Shahin Lockman, et al.

    Rationale: Early initiation of antiretroviral therapy (ART) leads to long-term viral suppression, reduces proviral reservoir size, and prolongs time to rebound. Since human immunodeficiency virus (HIV) is a lifelong disease, diagnostic monitoring after confirmed infection is typically not performed; therefore, little is known about the impact of early initiation and long-term ART on the sensitivity of assays that detect HIV antibodies and viral nucleic acid in children and adolescents. Patient concerns: Here we report 1 case of diagnosed and confirmed perinatal HIV-1C infection with longstanding viral suppression, who subsequently had a negative HIV-1 deoxyribonucleic acid (DNA) test, undetectable antibodies to HIV-1, and high CD4+ T cell count after 14 years of ART. Diagnosis: The patient was diagnosed with HIV in 2002 at 1 and 2 months of age using DNA polymerase chain reaction. At 8 months old, his viral load was 1210 HIV ribonucleic acid (RNA) copies/mL and CD4 T cell count was 3768 cells/mm3. Intervention: At the age of 9 months, highly active antiretroviral therapy comprising of zidovudine, nevirapine, and lamivudine was initiated. The patient remained on this treatment for 14 years 11 months and was virally suppressed. Outcomes: At the age of 14 years 4 months, the participant decided to visit a local voluntary HIV testing center, where a rapid HIV test came out negative and the viral load was undetectable (<400 HIV-1 RNA copies/mL). These results led to termination of ART which led to viral rebound within 9 months. Lessons: As more people with early HIV infection initiate early ART in the context of “Test and Treat all” recommendations, aspects of this report may become more commonplace, with both clinical and public health implications. If the possibility of functional cure (or false-positive diagnosis) is being considered, decisions to terminate ART should be made cautiously and with expert guidance, and may benefit from highly sensitive quantification of the proviral reservoir.